Enhancement of Conception Rate by EveCare after Ovulation Induction by Clomiphene Citrate followed by Intrauterine Insemination

Objective: In this comparative clinical trial the efficacy of EveCare and placebo was tried on 50 patients in the age group of 25-32 years, who underwent ovulation induction by clomiphene citrate and hCG followed by intrauterine insemination. Methods: The patients received EveCare or an identically prepared placebo and were advised to take the medication at a dose of 2 teaspoonfuls for 16 days after intrauterine insemination. The investigations included TSH, FSH, LH, Prolactin and E2 levels. Results: The results of these investigations showed that except for prolactin and E2 levels all the other values increased. The conception rates were high in the EveCare-treated group. Out of the 25 patients who took placebo only 7 conceived (28%) when compared to women who were on EveCare therapy. The rate of conception in EveCare therapy was 64% (16 out of 25). Conclusion: These observations indicate that EveCare can be an useful therapy in women with infertility. No untoward incidences were seen in any of the patients.